Evidence map›Paper›PMID 29415689›Full record

Observational studyBMC psychiatry2018

Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study.

Louise Öhlund, Michael Ott, Sofia Oja, Malin Bergqvist, Robert Lundqvist, Mikael Sandlund, Ellinor Salander Renberg, Ursula Werneke

Erratum issuedOpen access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Lithium: Old Drug, New tricks?Current psychiatry reports · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Lithium-discontinuation-induced treatment refractoriness revisited.International journal of bipolar disorders · 2024
    Review
  14. Ten-Year Trends in Lithium Prescribing in Alberta, Canada.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Lithium Treatment Induces Cardiac Dysfunction in Mice.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Louise ÖhlundSunderby Research Unit, Department of Clinical Sciences, Division of Psychiatry, Umeå University, Umeå, Sweden.
Michael OttDepartment of Public Health and Clinical Medicine, Division of Medicine, Umeå University, Umeå, Sweden.
Sofia OjaDepartment of Psychiatry, Sunderby Hospital, Luleå, Sweden.
Malin BergqvistDepartment of Psychiatry, Piteå Älvdals Hospital, Piteå, Sweden.
Robert LundqvistResearch and Innovation Unit, Luleå, Norrbotten Region, Sweden.
Mikael SandlundDepartment of Clinical Science, Division of Psychiatry, Umeå University, Umeå, Sweden.
Ellinor Salander RenbergDepartment of Clinical Science, Division of Psychiatry, Umeå University, Umeå, Sweden.
Ursula WernekeSunderby Research Unit, Department of Clinical Sciences, Division of Psychiatry, Umeå University, Umeå, Sweden. uwerneke@gmail.com.ORCID http://orcid.org/0000-0002-5023-3254
Umeå University · SESunderby sjukhus · SEArctic Business Incubator (Sweden) · SESkellefteå Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLithium remains first choice as maintenance treatment for bipolar affective disorder. Yet, about half of all individuals may stop their treatment at some point, despite lithium's proven benefits concerning the prevention of severe affective episodes and suicide.

methodsRetrospective cohort study in the Swedish region of Norrbotten into the causes of lithium discontinuation. The study was set up to (1) test whether patients with bipolar affective disorder or schizoaffective disorder, treated with lithium maintenance therapy, were more likely to discontinue lithium because of adverse effects than lack of therapeutic effectiveness, (2) explore gender differences, (3) understand the role of diagnosis and (4) identify who, patient or doctor, took the initiative to stop lithium. Review of medical records for all episodes of lithium discontinuation that had occurred between 1997 and 2013 with the intent to stop lithium for good.

resultsOf 873 patients treated with lithium, 54% discontinued lithium, corresponding to 561 episodes of lithium discontinuation. In 62% of episodes, lithium was discontinued due to adverse effects, in 44% due to psychiatric reasons, and in 12% due to physical reasons interfering with lithium treatment. The five single most common adverse effects leading to lithium discontinuation were diarrhoea (13%), tremor (11%), polyuria/polydipsia/diabetes insipidus (9%), creatinine increase (9%) and weight gain (7%). Women were as likely as men to take the initiative to stop lithium, but twice as likely to consult a doctor before taking action (p < 0.01). Patients with type 1 BPAD or SZD were more likely to discontinue lithium than patients with type 2 or unspecified BPAD (p < 0.01). Patients with type 1 BPAD or SZD were more likely to refuse medication (p < 0.01). Conversely, patients with type 2 or unspecified BPAD were three times as likely to discontinue lithium for lack or perceived lack of effectiveness (p < 0.001).

conclusionsStopping lithium treatment is common and occurs mostly due to adverse effects. It is important to discuss potential adverse effects with patients before initiation and continuously during lithium treatment, to reduce the frequency of potentially unnecessary discontinuations.

Indexed as

AdultAntimanic AgentsBipolar DisorderCohort StudiesEdemaFemaleHumansLithium CompoundsMaleRetrospective StudiesSwedenTremorWeight GainWithholding TreatmentAntimanic AgentsLithium CompoundsBipolar disorderComplianceLithiumPhysical healthSide effects

Identifiers

PMID29415689
PMCPMC5804058
OpenAlexW2796413314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.